ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: Results of a pilot study

被引:87
作者
Wilens, Timothy E.
Verlinden, Marleen H.
Adler, Lenard A.
Wozniak, Patricia J.
West, Scott A.
机构
[1] Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Yawkey Ctr Outpatient Care YAW 6A, Dept Psychiat, Boston, MA 02114 USA
[2] Abbott, Abbott Pk, IL USA
[3] NYU, Sch Med, Combined Psychiat & Neurol Adult ADHD Program, New York, NY USA
[4] New York Vet Affairs Harbor Healthcare Syst, Psychiat Serv, New York, NY USA
[5] CNS Healthcare, Orlando, FL USA
关键词
adult; ADHD; nicotinic receptor agonist; treatment; pilot study; pharmacology;
D O I
10.1016/j.biopsych.2005.10.029
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for adult attention-deficit/hyperactivity disorder (ADHD). Methods: Adults with ADHD received placebo, 2 mg, 4 mg, or 20 mg of ABT-089 for 2 weeks each in a randomized, double-blind, placebo-controlled. 4 x 4 Latin square design for a total of 8 weeks. In addition to the primary outcome, the Conners Adult ADHD Rating Scale (CAARS), secondary rating scales, and neuropsychological and safety assessments were completed. Results: A total of 11 adults with well-characterized ADHD completed this crossover study. ABT-089 b.i.d. was superior to placebo for the CAARS Total Symptom Score, which was the primary endpoint (placebo: 38.0 +/- 1.9; 2 mg b.i.d.: 32.2 +/- 1.9, one-tail p = .021; 4 mg b.i.d.: 33.2 +/- 1.9, p = .047; 20 mg b.i.d.: 33.5 +/- 1.9, p = .056). ABT-089 was also superior to placebo for the CAARS ADHD Index and Hyperactive/Impulsive scores and the Clinical Global Impression-ADHD Severity score. On the clinical efficacy endpoints, CAARS Total Symptom Score and CAARS Hyperactive/Impulsive score, a shallow inverted U-shaped dose-response curve was observed; however. the dose-response curve for attention and memory effects as measured by computerized cognitive testing seemed dose-linear. No clinically meaningful findings in safety assessments or side effect profile were observed effective in treating adult ADHD and that it is well tolerated. Conclusions: Data from this pilot study suggest that ABT-089 might be effective in treating adult ADHD and that it is well tolerated. On the basis of these promising results, larger, parallel-group ABT-089 studies of longer duration are warranted.
引用
收藏
页码:1065 / 1070
页数:6
相关论文
共 32 条
[1]  
[Anonymous], 1993, CROSSOVER TRIALS CLI
[2]  
Barkley RA, 2002, J CLIN PSYCHIAT, V63, P10
[3]   The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder [J].
Barkley, RA ;
Fischer, M ;
Smallish, L ;
Fletcher, K .
JOURNAL OF ABNORMAL PSYCHOLOGY, 2002, 111 (02) :279-289
[4]   Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type [J].
Biederman, J ;
Mick, E ;
Faraone, SV .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (05) :816-818
[5]  
Biederman J, 2004, J CLIN PSYCHIAT, V65, P3
[6]  
Conners C., 1999, Conners' Adult ADHD Rating Scales. Technical manual
[7]  
Conners CK, 1996, PSYCHOPHARMACOL BULL, V32, P67
[8]  
CONNERS CK, 1995, CONTINUOUS PERFORMAN
[9]  
Decker MW, 1997, J PHARMACOL EXP THER, V283, P247
[10]  
Faraone Stephen V, 2003, World Psychiatry, V2, P104